Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis

Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone and in combination with other agents for MM treatment. Daratumumab is though...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Naicker, Serika D, Feerick, Claire L, Lynch, Kevin, Swan, Dawn, McEllistrim, Cian, Henderson, Robert, Leonard, Niamh A, Treacy, Oliver, Natoni, Alessandro, Rigalou, Athina, Cabral, Joana, Chiu, Christopher, Sasser, Kate, Ritter, Thomas, O’Dwyer, Michael, Ryan, Aideen E
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7849715/
https://ncbi.nlm.nih.gov/pubmed/33552684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1859263
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky